Valuation: Ionis Pharmaceuticals, Inc.

Capitalization 12.4B 10.67B 9.76B 9.23B 17.05B 1,198B 17.32B 116B 45.3B 566B 46.55B 45.57B 1,970B P/E ratio 2026 *
-20.9x
P/E ratio 2027 * -59.5x
Enterprise value 12.18B 10.48B 9.59B 9.06B 16.75B 1,177B 17.01B 114B 44.49B 556B 45.72B 44.76B 1,935B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 8.05x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -
1 day+1.65%
1 week-3.27%
Current month+0.40%
1 month+0.25%
3 months-9.73%
6 months+2.65%
Current year-5.12%
1 week 71.93
Extreme 71.93
75.93
1 month 71.18
Extreme 71.175
79.19
Current year 68.9
Extreme 68.9
86.74
1 year 32
Extreme 32
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 19.59
Extreme 19.5927
86.74
Manager TitleAgeSince
Investor Relations Contact 60 30/06/2012
Chief Executive Officer 64 31/12/2019
Director of Finance/CFO 64 30/04/2000
Director TitleAgeSince
Director/Board Member 71 31/08/2000
Director/Board Member 81 31/12/1993
Director/Board Member 64 12/12/2005
Change 5d. change 1-year change 3-years change Capi.($)
+1.65%-3.27%+117.75%+91.53% 12.2B
+0.92%+3.86%-12.71%-14.79% 43.14B
+3.95%-2.47%+30.35%+32.73% 33.02B
+2.06%+0.26%+271.46%+481.55% 31.32B
-0.97%-0.51%+18.32%-14.01% 28.9B
-1.70%-5.83%+20.14%+12.65% 25.34B
+1.41%-0.92% - - 14.78B
+1.44%+0.26%+131.52%+4,144.54% 13.35B
+1.34%+5.61%+9.14%+2.71% 12.5B
+0.47%-0.45%+37.59%+100.05% 11.99B
Average +1.06%-0.92%+69.28%+537.44% 22.65B
Weighted average by Cap. +1.09%-1.21%+64.94%+345.30%

Financials

2026 *2027 *
Net sales 890M 765M 701M 662M 1.22B 85.97B 1.24B 8.31B 3.25B 40.58B 3.34B 3.27B 141B 1.48B 1.28B 1.17B 1.1B 2.04B 143B 2.07B 13.85B 5.42B 67.67B 5.57B 5.45B 236B
Net income -595M -512M -468M -442M -818M -57.46B -831M -5.55B -2.17B -27.12B -2.23B -2.19B -94.48B -216M -185M -170M -160M -296M -20.83B -301M -2.01B -788M -9.83B -809M -792M -34.25B
Net Debt -220M -189M -173M -164M -303M -21.28B -308M -2.06B -805M -10.05B -827M -809M -34.99B -460M -396M -362M -342M -632M -44.43B -642M -4.29B -1.68B -20.97B -1.73B -1.69B -73.05B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
20/05/26 75.06 $ +1.65% 2,005,309
19/05/26 73.84 $ +1.82% 1,519,490
18/05/26 72.52 $ -2.30% 2,211,491
15/05/26 74.23 $ -1.92% 2,119,183
14/05/26 75.68 $ -2.47% 1,798,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
75.06USD
Average target price
100.92USD
Spread / Average Target
+34.45%

Quarterly revenue - Rate of surprise